On April 26, 2024, the Journal of Clinical Neuroscience published “Antipsychotic medications associated with increased length of hospital stay in autoimmune encephalitis and multiple sclerosis: A retrospective study” by Stephen Sai Folmsbee a, Gavin Hui b, Ye Yuan b, Saurabh Gombar b, May Han c, Scheherazade Le d.
a Stanford University, Department of Psychiatry, 401 Quarry Rd, Palo Alto, CA 94304, USA
b Atropos Health (www.atroposhealth.com), Palo Alto, CA 94304, USA
c Stanford University, Department of Neurology, Neuroimmunology Division, 213 Quarry Rd, Palo Alto, CA 94304, USA
d Stanford University, Department of Neurology, Stanford Comprehensive Epilepsy Center, 213 Quarry Rd, Palo Alto, CA 94304, USA
Read the paper in Journal of Clinical Neuroscience: https://authors.elsevier.com/c/1i~q9_M01YvBMd
Key highlights:
-
Antipsychotic medications associated with worse hospital length-of-stay in autoimmune encephalitis and multiple sclerosis.
-
Typical antipsychotics associated with worse mortality, but decreased hospital length-of-stay, when compared to atypical antipsychotics in multiple sclerosis.
-
Antidepressant medications associated with increased hospital length-of-stay in multiple sclerosis.
-
Citalopram and fluoxetine were associated with worse hospital length-of-stay for those with multiple sclerosis when compared to other antidepressants.
-
Black patients with neuroinflammatory disorders were more likely to receive antipsychotics, but less likely to receive antidepressants.
Conclusions:
There was a statistically significant increase in LOS associated with APM use in non-infectious encephalitis and MS, as well as with SSRI use in MS. These data reflect the importance of these medications in these neuroinflammatory disorders and suggest that further investigation into their risks and benefits would be warranted.
Abbreviations
APM = antipsychotic medication
MS = multiple sclerosis
LOS = length of stay
SSRI = selective-serotonin reuptake inhibitor
PSM = propensity-score matching
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), contact info@atroposhealth.com